Type 1 diabetes: Global prevalence is set to double by 2040, study estimates

Mahase, Elisabeth

doi:10.1136/bmj.o2289

Cited by 8 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Commenting on the findings, Hilary Nathan, policy director for the non-profit organisation Juvenile Diabetes Research Foundation, said, “100 years ago, the patent for insulin was sold for $1 in order that this life saving drug would benefit all. Our research2 shows, however, that that ambition has not been realised: more than 3.8 million people with type 1 diabetes would be alive today if they had had access to diagnosis, insulin, and basic glucose testing treatments. And the benefits of insulin have been, in the main, restricted to developed, rather than developing countries.…”

mentioning

confidence: 79%

Insulin access still “severely limited” in low income countries, report finds

Mahase¹

2022

BMJ

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 79%

Insulin access still “severely limited” in low income countries, report finds

Mahase¹

2022

BMJ

Self Cite

View full text Add to dashboard Cite

“…Autoimmune diabetes is a relatively common chronic disease with an increasing number of afflicted subjects around the globe. The number of T1D subjects has been suggested to double by 2040, partially driven by a significantly and unabated globally increasing incidence 163 . To lessen the significant disease burden to subjects, families and societies, effective interventions such as timely diagnosis, intensive management of glucose control combined with novel treatment modalities preserving β‐cell function are essential to increase quality of life and to keep health care costs under control.…”

Section: Final Remarksmentioning

confidence: 99%

“…The number of T1D subjects has been suggested to double by 2040, partially driven by a significantly and unabated globally increasing incidence. 163 To lessen the significant disease burden to subjects, families and societies, effective in- To be optimistic, the future will be bright, provided that we take disease evolution and clinical presentation of T1D wisely into consideration to deliver personalised T1D management therapies.…”

Section: Final Remarksmentioning

confidence: 99%

Type 1 diabetes: A new vision of the disease based on endotypes

Weston,

Boehm,

Pozzilli

2024

Diabetes Metabolism Res

View full text Add to dashboard Cite

Diagnosis and management of type 1 diabetes (T1D) have remained largely unchanged for the last several years. The management of the disease remains primarily focused on its phenotypical presentation and less on endotypes, namely the specific biological mechanisms behind the development of the disease. Furthermore, the treatment of T1D is essentially universal and indiscriminate—with patients administering insulin at varying dosages and frequencies to maintain adequate glycaemic control. However, it is now well understood that T1D is a heterogeneous disease with many different biological mechanisms (i.e. endotypes) behind its complex pathophysiology. A range of factors, including age of onset, immune system regulation, rate of β‐cell destruction, autoantibodies, body weight, genetics and the exposome are recognised to play a role in the development of the condition. Patients can be classified into distinct diabetic subtypes based on these factors, which can be used to categorise patients into specific endotypes. The classification of patients into endotypes allows for a greater understanding of the natural progression of the disease, giving rise to more accurate and patient‐centred therapies and follow‐up monitoring, specifically for other autoimmune diseases. This review proposes 6 unique endotypes of T1D based on the current literature. The recognition of these endotypes could then be used to direct therapeutic modalities based on patients' individual pathophysiology.

show abstract

“…Its prevalence is increasing in the world, and this issue shows the need for adequate attention to the diagnosis and adequate and timely treatment of this disease all over the world. The highest prevalence of this disease will be in low‐ and relatively low‐income countries 2–4 …”

Section: Introductionmentioning

confidence: 99%

“…The highest prevalence of this disease will be in low-and relatively lowincome countries. [2][3][4] Insulin was one of the first drug treatments for diabetes and is still one of the first lines of treatment. Since the discovery of insulin in 1921 and until now, this substance has saved many people.…”

mentioning

confidence: 99%

Efficacy of teplizumab for treatment of type 1 diabetes: A meta‐analysis of randomized controlled trials

Heidari,

Shafiee,

Noorian

et al. 2024

Diabetes Metabolism Res

View full text Add to dashboard Cite

BackgroundThe management of Type 1 Diabetes Mellitus (T1DM) is a significant clinical challenge. This study evaluated the efficacy of teplizumab, an immunomodulatory drug, in patients with T1DM, using a systematic review and meta‐analysis approach.MethodsWe systematically searched multiple databases including Medline, Scopus, and others up to 10 January 2024, without language or regional restrictions. We included randomized controlled trials (RCTs) comparing teplizumab with placebo in T1DM patients.ResultsOur analysis incorporated 8 RCTs, predominantly involving participants aged 7–35 years, diagnosed with T1DM and treated with 14‐day courses of teplizumab. The primary outcomes included insulin use, C‐peptide levels, and HbA1c levels. We observed a significant reduction in insulin use in the teplizumab group standardised mean difference of −0.50 (95% Confidence Interval [CI]: −0.76 to −0.23, p < 0.001; I2 = 49%). C‐peptide levels were consistently higher in the teplizumab group, indicating improved endogenous insulin production. However, no significant change was noted in HbA1c levels between the groups. Quality assessment indicated a low risk of bias in most studies.ConclusionsTeplizumab has a significant impact on reducing insulin dependence and enhancing endogenous insulin production in T1DM patients. However, its effect on long‐term glycaemic control, as indicated by HbA1c levels, remains inconclusive.

show abstract

Type 1 diabetes: Global prevalence is set to double by 2040, study estimates

Cited by 8 publications

References 1 publication

Insulin access still “severely limited” in low income countries, report finds

Insulin access still “severely limited” in low income countries, report finds

Type 1 diabetes: A new vision of the disease based on endotypes

Efficacy of teplizumab for treatment of type 1 diabetes: A meta‐analysis of randomized controlled trials

Contact Info

Product

Resources

About